Peptides AcademyGLP-1 + GHS (Semaglutide + Tesamorelin or CJC/Ipa)
A newer 'metabolic recomposition' pairing some practitioners use: a GLP-1 agonist for appetite and total weight reduction, combined with a GHS for preserving lean mass and targeting visceral fat.
Quick Comparison
| Property | peptide | The Metabolic Stack: GLP-1 + GHS |
|---|---|---|
| Source | Salmon DNA fragments | Various sources |
| Primary Mechanism | A2A receptor activation, DNA repair | Varies by ingredient |
| Key Benefits | Tissue regeneration, anti-inflammation, collagen boost | Multiple skin benefits |
| Best Time to Apply | AM or PM | AM or PM |
| Can Combine? | Generally compatible — check specific guidelines. | |
How to Use Together
Not a validated therapeutic combination — this is an off-label pattern seen in metabolic clinics. The reasoning: GLP-1 agonists produce 10–20% total weight loss but roughly 25–40% of that loss is lean mass. GHS peptides theoretically attenuate lean-mass loss. Published head-to-head evidence is absent.
Safety Notes
Stacking two hormonally active peptide classes amplifies monitoring requirements. Track IGF-1, fasting glucose, HbA1c, lipid panel, and lean/fat mass via DEXA or BIA. Do not self-combine without medical supervision.
Recommended Products (3)
CJC-1295 + Ipamorelin
Research-Grade
The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Tesamorelin
Egrifta
FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.